Adjuvant Capital

Adjuvant Capital is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges. It focuses on historically overlooked market segments, leveraging expertise to translate opportunities into social and financial returns. The firm's investment model is heavily influenced by global trends such as climate change and antimicrobial resistance.

Adjuvant Capital favicon
Founded 2012 ยท Venture Capital
New York (United States), Zurich (Switzerland), San Francisco (United States)
Investment Stages
Series A
Series B
Series C
Markets
Life sciences
Drugs
Vaccines
Diagnostics
Medical devices
Portfolio Companies

LimmaTech Biologics, Memo Therapeutics, Curevo Vaccine, Antiva Biosciences, Pulmocide, Excision BioTherapeutics, Frontier Nutrition, VitriVax, MinervaX, Evofem, Univercells, YS Biopharma, ChromaCode, 54gene, Codagenix, AN2 Therapeutics, Themis, InDevR, X-Vax

Share this page